A recent real-world study on AYVAKIT has shown significant improvements in symptoms related to Indolent Systemic Mastocytosis (ISM). 12 data presentations were showcased at the 2026 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), underscoring Blueprint Medicines' leading role in enhancing care for Systemic Mastocytosis (SM). The study was conducted by Blueprint Medicines, now a subsidiary of Sanofi, and was revealed in Cambridge, Massachusetts on February 28, 2026.